Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials

Autor: Philippe Moreau, Keith A. Stewart, Meletios Dimopoulos, David Siegel, Thierry Facon, James Berenson, Noopur Raje, Jesus G. Berdeja, Robert Z. Orlowski, Hui Yang, Haijun Ma, Zandra Klippel, Anita Zahlten‐Kumeli, Khalid Mezzi, Karim Iskander, Maria‐Victoria Mateos

Publikováno v: Cancer Medicine, Vol 9, Iss 9, Pp 2989-2996 (2020)

Abstract Combination of carfilzomib with dexamethasone (Kd) is approved for use in relapsed and/or refractory multiple myeloma (RRMM), with carfilzomib administered twice weekly at 56 mg/m2 (Kd56 BIW) or once weekly at 70 mg/m2 (Kd70 QW). Post hoc cr

Externí odkaz: https://doaj.org/article/228d0e9245d94238b5930f7eee8ce724

Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

Autor: Michael A. Thompson, Mario Boccadoro, Xavier Leleu, Jorge Vela-Ojeda, Frits van Rhee, Katja C. Weisel, Robert M. Rifkin, Saad Z. Usmani, Roman Hájek, Gordon Cook, Rafat Abonour, Mira Armour, Kathryn E. Morgan, Su-Peng Yeh, Caitlin L. Costello, Jesus G. Berdeja, Faith E. Davies, Jeffrey A. Zonder, Hans C. Lee, Jim Omel, Andrew Spencer, Evangelos Terpos, Vania T.M. Hungria, Noemi Puig, Chengcheng Fu, Renda H. Ferrari, Kaili Ren, Dawn Marie Stull, Ajai Chari

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 23:e171-e181

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d129f8aad7fce7c7e3e3c6dbfc6c05ad
https://doi.org/10.1016/j.clml.2022.12.003

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

Autor: Ajai Chari, Monique C. Minnema, Jesus G. Berdeja, Albert Oriol, Niels W.C.J. van de Donk, Paula Rodríguez-Otero, Elham Askari, María-Victoria Mateos, Luciano J. Costa, Jo Caers, Raluca Verona, Suzette Girgis, Shiyi Yang, Rachel B. Goldsmith, Xiang Yao, Kodandaram Pillarisetti, Brandi W. Hilder, Jeffery Russell, Jenna D. Goldberg, Amrita Krishnan

Publikováno v: Chari, A, Minnema, M C, Berdeja, J G, Oriol, A, van de Donk, N W C J, Rodríguez-Otero, P, Askari, E, Mateos, M-V, Costa, L J, Caers, J, Verona, R, Girgis, S, Yang, S, Goldsmith, R B, Yao, X, Pillarisetti, K, Hilder, B W, Russell, J, Goldberg, J D & Krishnan, A 2022, ' Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma ', The New England journal of medicine, vol. 387, no. 24, pp. 2232-2244 . https://doi.org/10.1056/NEJMoa2204591
The New England journal of medicine, 387(24), 2232-2244. Massachussetts Medical Society

BACKGROUND: G protein-coupled receptor, family C, group 5, member D (GPRC5D) is an orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody against CD3 and GPRC5D, redirects T cells to mediate killing of GPRC5D-expressi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8606346460e6e7b33433741bd8ffff5
https://doi.org/10.1056/nejmoa2204591

Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

Autor: Katja Weisel, Amrita Krishnan, Jordan M. Schecter, Martin Vogel, Carolyn C. Jackson, William Deraedt, Tzu-min Yeh, Arnob Banerjee, Fevzi Yalniz, Tonia Nesheiwat, Suzy Van Sanden, Joris Diels, Satish Valluri, Saad Z. Usmani, Jesus G. Berdeja, Sundar Jagannath, Tom Martin

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 22:690-701

This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-cel; CARTITUDE-1), a chimeric antigen receptor (CAR)-T-cell therapy, versus 3 non-CAR-T therapies (belantamab mafodotin [DREAMM-2], selinexor plus dexamethasone [STORM

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0fa0c9b8068510e2b64e6488ffdcacd
https://doi.org/10.1016/j.clml.2022.04.025

Data from A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia

Autor: Jesus G. Berdeja, Mihaela Obreja, Michael R. Savona, Andrzej Jakubowiak, Noopur Raje, Jonathan Kaufman, Ashraf Badros, David Siegel, Ravi Vij, Irene M. Ghobrial

Purpose:The oral proteasome inhibitor oprozomib has shown preclinical antitumor activity. Here, we report phase Ib/II study results investigating single-agent oprozomib in patients with relapsed multiple myeloma and Waldenström macroglobulinemia.Pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::025f219b64c4ee92355dddf024bed1bb
https://doi.org/10.1158/1078-0432.c.6528390